Predictive Oncology to Present Cutting-Edge AI Innovations
PITTSBURGH — Predictive Oncology Inc. (NASDAQ: POAI) is gearing up to participate in a much-anticipated virtual event, the H.C. Wainwright 26th Annual Global Investment Conference. This year's conference will take place from September 9 to September 11, offering a stage to unveil significant advancements in AI-driven drug discovery.
Details of the Event Presentation
Predictive Oncology's presentation will be available on-demand starting September 9 at 7:00 am (ET). Attendees can easily access the presentation through the dedicated conference platform, allowing them to engage with the insights shared at their own convenience.
One-on-One Meetings
In addition to the main presentation, the management team at Predictive Oncology will hold one-on-one meetings throughout the conference. Interested investors are encouraged to contact their H.C. Wainwright representatives to schedule personalized discussions.
About Predictive Oncology Inc.
Predictive Oncology is at the leading edge of merging artificial intelligence and machine learning with drug discovery, with a mission to enhance treatment options for cancer patients worldwide. Their advanced platform, PEDAL, boasts an impressive 92% success rate in accurately predicting how tumors respond to specific drug compounds. This capability allows for a more informed selection of suitable drug/tumor combinations for in-vitro testing.
Industry-Leading Resources
With access to a vast biobank containing over 150,000 assay-capable human tumor samples, Predictive Oncology offers one of the most comprehensive AI-driven drug discovery solutions available. Their proprietary facilities adhere to CLIA standards and Good Manufacturing Practices (GMP), effectively supporting both academic and industry partners.
Investor Contact Information
For inquiries related to investor relations, please reach out to Tim McCarthy from LifeSci Advisors, LLC. He can be contacted at tim@lifesciadvisors.com. Predictive Oncology is dedicated to transparency and encouraging investor engagement.
Frequently Asked Questions
What is the primary focus of Predictive Oncology?
Predictive Oncology's main focus is to leverage AI and machine learning to improve drug discovery and treatment options for cancer patients.
When will the conference presentation be accessible?
The presentation will be available on-demand starting on September 9 at 7:00 am (ET).
How can investors schedule one-on-one meetings?
Investors can schedule one-on-one meetings by reaching out to their H.C. Wainwright representative.
What makes the PEDAL platform important?
The PEDAL platform is important because it enables high accuracy in predicting how effective drug compounds will be on various tumor types, which helps in creating tailored treatment strategies.
Who should I contact for more information about investor relations?
You can reach out to Tim McCarthy of LifeSci Advisors, LLC at tim@lifesciadvisors.com for more information.
